摘要
特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)是一种原因不明的、进行性的、局限于肺部以纤维化伴蜂窝状改变为特征的疾病[1],HRCT扫描可见胸膜下、两肺基底部网格状阴影和蜂窝影,肺功能测试示限制性通气和弥散功能障碍。近20余年来其发病率增加,中位生存期为3~5年[2],5年生存率20%~40%。在西医领域,目前治疗IPF仍缺乏有效药物,关于抗肺纤维化新药的多期临床研究仍在进行中。根据的IPF症状通常可将其归属与祖国医学"肺痹"、"肺痿"等范畴,中医将辨病与辨证相结合,对IPF的防治具有一定的功效。
Idiopathic pulmonary fibrosis is a disease which is agnogenic,progressive and confined to the lung characterized by fibrosis with honeycomb change. HRCT scanning shows grid shadow and honeycomb in subpleural or two bases of lungs and pulmonary function test showed restrictive ventilation and diffuse dysfunction. Its incidence has been increasing in nearly 20 years. The median survival period was 3 to 5 years and the 5-year survival rate was 20%- 40%. In Western medicine,there was no effective drugs in the treatment of IPF and the multiphase on pulmonary fibrosis drug resistance is still on. According to the IPF symptoms,it can be categorized to the Fei Bi and Fei Wei in TCM. Combining disease and syndrome differentiation of traditional Chinese medicine is effective to the prevention of IPF. Now this paper discussed recent advances in the Chinese and western medicine treatment of IPF as follows.
出处
《中华中医药学刊》
CAS
北大核心
2016年第2期402-405,共4页
Chinese Archives of Traditional Chinese Medicine
基金
上海市中医学一流学科创新基金项目(1039)
关键词
特发性肺纤维化
治疗进展
idiopathic pulmonary fibrosis
treatment progress